VITAL - VIrtual Twins as tools for personalised clinicAL care
VITAL - VIrtual Twins as tools for personalised clinicAL care
批准号:
10106637
负责人:
金额:
$140.37万
依托单位国家:
英国
项目类别:
EU-Funded
财政年份:
2024
资助国家:
英国
项目状态:
未结题
起止时间:
2024 至 --
中文摘要
VITAL将提供一个全面的临床验证的多尺度、多器官建模平台,该平台由在临床和可穿戴技术中获得的个体患者数据驱动并可以代表这些数据。该平台将创建一个虚拟人类双胞胎,用于对具有全身性影响和高风险并存的复杂、多因素心血管疾病的内科(药理)或外科(介入)治疗进行个性化和特定性别的优化。肾脏和大脑:系统性高血压、心力衰竭(有/没有保留的射血分数)和血流动力学复杂的房间隔缺损。与医疗保健专业人员共同创建的用户友好的界面将提供访问该技术的途径。该平台整合了现有的心、肺和全身循环的多尺度和多器官模型及其调节机制,并通过纳入目前缺失的基于生物物理学和生理学的组件(与肾脏相关的血压控制、激素作用、特定血管区域的平滑肌细胞功能,以及心脏和动脉生长和重塑机械生物机制),推动了最新技术的发展。到该项目结束时,该平台将在法国和英国的5项临床研究的200多名患者中得到验证和测试,以优化对顽固性系统性高血压、心力衰竭或房间隔缺陷患者的治疗。VITAL的一个独特方面是它专注于监测患者的心理健康,以了解他们对数字健康技术的期望和保留意见。关键技术将符合VPHi和伊迪丝虚拟双胞胎生态系统,并直接为其做出贡献。这将进一步释放新的数字工具的潜力,这些工具智能地结合基于物理的多尺度模型、人工智能和数据的力量,为所有人提供更好的医疗保健。
英文摘要
VITAL will deliver a comprehensive clinically validated multi-scale, multi-organ modelling platform that is driven by and can represent individual patient data acquired, both in the clinic and from wearable technology. The platform will create a virtual human twin for individualised and sex-specific optimisation of medical (pharmacological) orsurgical (interventional) therapy for complex, multifactorial cardiovascular disorders that have systemic impact and high risk of comorbidities of a.o. the kidney and brain: systemic hypertension, heart failure (with/without preserved ejection fraction) and hemodynamically complicated atrial septal defects.User-friendly interfaces, co-created with healthcare professionals, will provide access to the technology. The platform consolidates existing multi-scale and multi-organ models of the heart, lung and systemic circulation and their regulatory mechanisms, and advances the state-of-the art by incorporating currently missing biophysics-based, physiology-underpinned components (kidney-related blood pressure control, hormonal actions, vascular region-specific smooth muscle cell functionality, and cardiac and arterial growth and remodelling mechano biological mechanisms). By the end of the project, the platform will have been validated and tested in more than 200 patients across 5 clinical studies in France and the UK to optimise the treatment of patients with resistant systemic hypertension, heart failure or atrial septum defects. A unique aspect of VITAL is its focus on monitoring the mental health of patients to understand their expectations and reservations towards digital health technology. VITAL technology will be compliant with and contribute directly to the VPHi and EDITH virtual twin ecosystem. This will further unlock the potential of new digital tools that intelligently combine the power of physics-based multi-scale models, artificial intelligence and data to provide better health care for all.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金